ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sandoz to commercialise Shionogi’s Rizmoic in European markets
April 23, 2019Sandoz to commercialise Shionogi’s Rizmoic in European markets... -
Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries
April 12, 2019Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative... -
Shionogi receives Marketing Authorisation for Rizmoic (naldemedine) for the treatment of opioid-induced constipation in adults
February 24, 2019Shionogi & Co., Ltd. (hereafter "Shionogi"), a research-driven pharmaceutical company, announced today thatthe European Commission(EC) has granted Marketing Authorisation(MA) for Rizmoic® (naldemedine), for the treatment of opioid-induced constipation (OI
Pharma Sources Insight January 2025
